Article Text
PDF
Abstract
A review of National Health Service spending in England on prescription drugs used in Parkinsonism over the last 10 years shows that spending has risen rapidly and that newly introduced drugs are quickly and expensively adopted. This paper explores the gains and costs of such prescribing.
Statistics from Altmetric.com
Footnotes
Contributors PM retrieved and analysed data, wrote and submitted the manuscript.
Competing interests The author has received no lecture fees or honoraria directly from the pharmaceutical industry over the last 6 years though, on five occasions over the same period, has received a speaker fee or honorarium from a sponsored educational meeting and has received hospitality at other sponsored meetings. He also sits, unpaid, on the steering committee of the PDMED trial.
Provenance and peer review Not commissioned; externally peer reviewed. This paper was reviewed by Paul Worth, Norwich, UK.
Linked Articles
- Editors' choice
Read the full text or download the PDF:
Other content recommended for you
- Initial drug treatment in Parkinson’s disease
- Initial management of Parkinson’s disease
- Parkinson’s disease: etiopathogenesis and treatment
- What to do when people with Parkinson's disease cannot take their usual oral medications
- Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study
- Developments in the treatment of Parkinson's disease
- ▼ Safinamide for Parkinson’s disease
- Present and future drug treatment for Parkinson’s disease
- Impulse control disorders in Parkinson’s disease: a national Swedish registry study on high-risk treatments and vulnerable patient groups
- Pharmacological treatment of Parkinson's disease